Literature DB >> 33430926

High miR-324-5p expression predicts unfavorable prognosis of gastric cancer and facilitates tumor progression in tumor cells.

Zhong Zheng1, Jun Li2, Junyan An1, Yikuan Feng1, Lirong Wang3.   

Abstract

BACKGROUND: Gastric cancer (GCa) is one of the six major malignancies in the world with low survival rate. Although there are advances in therapeutic approaches, the prognosis of patients with GCa remains not optimistic. Therefore, this study aimed to evaluate the prognostic value of miR-324-5p, as well as its functional role in GCa progression.
METHODS: The expression of miR-324-5p in tumor tissues and cell lines was examined using real-time quantitative PCR. The prognostic value of miR-324-5p in patients with GCa was evaluated by Kaplan-Meier survival curve and Cox regression analysis. Gain- and loss-of-function experiments were performed to evaluate the biological function of miR-324-5p during the progression of GCa, and a target gene of miR-324-5p was proposed.
RESULTS: The expression of miR-324-5p was up-regulated in GCa tissues and cell lines. Patients with high expression of miR-324-5p had more cases with positive lymph node metastasis, advanced TNM stage, and worse overall survival compared with patients with low expression. The elevated miR-324-5p was an independent prognostic indicator of GCa. In addition, the inhibition of miR-324-5p could suppress GCa cell proliferation, migration and invasion and promote cell apoptosis, and PTEN was demonstrated to serve as a direct target of miR-324-5p in GCa progression.
CONCLUSION: The present study indicates that miR-324-5p overexpression predicts poor prognosis in GCa patients, and the reduction of miR-324-5p can inhibit GCa biological processes. PTEN is a target gene of GCa, which may mediate the biological function of miR-324-5p in GCa progression.

Entities:  

Keywords:  Invasion; MicroRNA-324-5p, gastric cancer; Migration; PTEN; Prognosis; Proliferation

Year:  2021        PMID: 33430926      PMCID: PMC7798222          DOI: 10.1186/s13000-020-01063-2

Source DB:  PubMed          Journal:  Diagn Pathol        ISSN: 1746-1596            Impact factor:   2.644


  37 in total

1.  MicroRNA-28 promotes cell proliferation and invasion in gastric cancer via the PTEN/PI3K/AKT signalling pathway.

Authors:  Lihua Li; Xiongjie Zhu; Tao Shou; Libo Yang; Xiaozhen Cheng; Jinting Wang; Lian Deng; Yanfang Zheng
Journal:  Mol Med Rep       Date:  2017-12-18       Impact factor: 2.952

2.  Peripheral blood circulating microRNA-4636/-143 for the prognosis of cervical cancer.

Authors:  Sheng Yin; Min Yang; Xianping Li; Kan Zhang; Jingjing Tian; Can Luo; Ruiyang Bai; Yangfan Lu; Min Wang
Journal:  J Cell Biochem       Date:  2019-08-12       Impact factor: 4.429

Review 3.  Potential application of tumor suppressor microRNAs for targeted therapy in head and neck cancer: A mini-review.

Authors:  Isaac Olatunji
Journal:  Oral Oncol       Date:  2018-11-09       Impact factor: 5.337

4.  Sonic hedgehog signaling promotes motility and invasiveness of gastric cancer cells through TGF-beta-mediated activation of the ALK5-Smad 3 pathway.

Authors:  Young A Yoo; Myoung Hee Kang; Jun Suk Kim; Sang Cheul Oh
Journal:  Carcinogenesis       Date:  2008-01-03       Impact factor: 4.944

5.  microRNA-32-5p targets KLF2 to promote gastric cancer by activating PI3K/AKT signaling pathway.

Authors:  Qingqing Wang; Yuan He; Weiqiong Kan; Fucai Li; Xiangjun Ji; Xuewen Wu; Xinyue Wang; Yue Zhang; Jinlian Chen
Journal:  Am J Transl Res       Date:  2019-08-15       Impact factor: 4.060

6.  Expression of Circulating miR-155, miR-21, miR-221, miR-30a, miR-34a and miR-29a: Comparison of Colonic and Rectal Cancer.

Authors:  Enikő Orosz; István Kiss; Zoltán Gyöngyi; Tímea Varjas
Journal:  In Vivo       Date:  2018 Nov-Dec       Impact factor: 2.155

7.  Comprehensive identification of microRNA arm selection preference in lung cancer: miR-324-5p and -3p serve oncogenic functions in lung cancer.

Authors:  Min-Hsi Lin; You-Zuo Chen; Mei-Yu Lee; Ken-Pen Weng; Hong-Tai Chang; Shou-Yu Yu; Bo-Jhu Dong; Fan-Rong Kuo; Li-Tzu Hung; Li-Feng Liu; Wei-Shone Chen; Kuo-Wang Tsai
Journal:  Oncol Lett       Date:  2018-04-24       Impact factor: 2.967

8.  Serum miR-379 expression is related to the development and progression of hypercholesterolemia in non-alcoholic fatty liver disease.

Authors:  Kinya Okamoto; Masahiko Koda; Toshiaki Okamoto; Takumi Onoyama; Kenichi Miyoshi; Manabu Kishina; Tomomitsu Matono; Jun Kato; Shiho Tokunaga; Takaaki Sugihara; Akira Hiramatsu; Hideyuki Hyogo; Hiroshi Tobita; Shuichi Sato; Miwa Kawanaka; Yuichi Hara; Keisuke Hino; Kazuaki Chayama; Yoshikazu Murawaki; Hajime Isomoto
Journal:  PLoS One       Date:  2020-02-27       Impact factor: 3.240

9.  Hsa_circ_0003159 inhibits gastric cancer progression by regulating miR-223-3p/NDRG1 axis.

Authors:  Jingyu Wang; Weize Lv; Zhidong Lin; Xiao Wang; Juyuan Bu; Yonghui Su
Journal:  Cancer Cell Int       Date:  2020-02-19       Impact factor: 5.722

10.  Upregulation of miR-324-5p Inhibits Proliferation and Invasion of Colorectal Cancer Cells by Targeting ELAVL1.

Authors:  Chijiang Gu; Mingyuan Zhang; Weiliang Sun; Changzheng Dong
Journal:  Oncol Res       Date:  2018-01-31       Impact factor: 5.574

View more
  3 in total

1.  Circular RNA circ_0079593 facilitates glioma development via modulating miR-324-5p/XBP1 axis.

Authors:  Pengcheng Wang; Tong Wang; Lei Dong; Zhenkuan Xu; Shouzhong Guo; Chengyue Chang
Journal:  Metab Brain Dis       Date:  2022-07-06       Impact factor: 3.655

Review 2.  A review on the role of miRNA-324 in various diseases.

Authors:  Sepideh Kadkhoda; Bashdar Mahmud Hussen; Solat Eslami; Soudeh Ghafouri-Fard
Journal:  Front Genet       Date:  2022-08-10       Impact factor: 4.772

3.  Interferon-mediated repression of miR-324-5p potentiates necroptosis to facilitate antiviral defense.

Authors:  Xiaoyan Dou; Xiaoliang Yu; Shujing Du; Yu Han; Liang Li; Haoran Zhang; Ying Yao; Yayun Du; Xinhui Wang; Jingjing Li; Tao Yang; Wei Zhang; Chengkui Yang; Feng Ma; Sudan He
Journal:  EMBO Rep       Date:  2022-06-23       Impact factor: 9.071

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.